A
Alcista
Alcista · 25%BLFS
$26.69
Precio del escenario
$38.610
+1.355 (+3.51%)Al cierre
Loading chart…
- Máximo
- 38.830
- Apertura
- 37.160
- Precio medio ponderado por volumen
- 38.13
- Volumen
- 4.45M
- Capitalización
- 944.41M
- Mínimo
- 36.950
- Importe
- 169.53M
- EV/EBITDA, TTM
- 164.02
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Análisis de IA of BioLife Solutions, Inc. (BLFS)
MantenerBioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
Recomendaciones de analistas (3)
-13.88% Potencial de caída
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 38.61
Mínimo
32.00
Promedio
33.25
Máximo
34.00
Benchmark
Mantener
—
2026-08-10
Benchmark
2026-08-10
Precio objetivo
—
Mantener
Jefferies
Mantener
$31
2026-07-23
Jefferies
2026-07-23
Precio objetivo
$31
Mantener
H.C. Wainwright
Neutral
$31
2026-07-23
H.C. Wainwright
2026-07-23
Precio objetivo
$31
Neutral
TD Cowen
Mantener
$31
2026-07-22
TD Cowen
2026-07-22
Precio objetivo
$31
Mantener
Craig-Hallum
Mantener
$31
2026-07-22
Craig-Hallum
2026-07-22
Precio objetivo
$31
Mantener
Métricas de valoración
El PER previsto actual de BioLife Solutions, Inc. (BLFS) es 238.10, frente a su media de 5 años de -160.78.
Escenarios de precio de Alphio AI para BLFS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BLFS en cartera
Cronología de eventos
Noticias
8.510-06FoolFreshworks Joins S&P SmallCap 600 Index
2.009-23NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.509-11PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
8.508-18NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
7.007-28PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
Preguntas frecuentes sobre BLFS, respondidas por Alphio AI
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.